Legend Biotech expects to achieve company-wide operating profit in 2026, supported by massive expansion of its Raritan manufacturing facility. The company develops and commercializes advanced oncology treatments primarily through its Johnson & Johnson collaboration, while diversifying its pipeline into allogeneic and in vivo therapies. CARVYKTI has cemented its status as the undisputed leader in multiple myeloma CAR-T cell therapy with record-breaking performance.
Cyborg Score Rationale
The expanded Raritan facility is the largest cell therapy manufacturing facility in the U.S., capable of treating 10,000 patients annually. Triple-class-exposed patients achieved median progression-free survival of 50.4 months after single infusion, and the company targets 2026 profitability with strong cash position.
Top Insights
Q3 2025 results highlighted $524M CARVYKTI net trade sales and approximately $1.0B in cash and time deposits
Phase 3 CARTITUDE-6 trial enrollment for newly diagnosed, transplant-eligible patients completed in August 2025, potentially opening frontline multiple myeloma market
Management dosed first patient using in vivo platform for dual CD20/CD19-targeted therapy with initial human data expected in second half of 2026
Recent positive clinical updates met with muted market reactions, suggesting potential valuation gap between clinical achievement and stock performance
Yescarta (Axicabtagene Ciloleucel) — CAR-T cell therapy for lymphoid malignancies
Abecma (Idecabtagene Vicleucel) — CAR-T cell therapy for multiple myeloma
Recent Developments
(February 2026) Legend Biotech to present CARVYKTI data at Tandem Meetings with focus on earlier-line use and safety
(January 2026) Company outlined 2026 priorities including profitability targets and continued CARVYKTI global expansion at J.P. Morgan Healthcare Conference
(December 2025) ASH 2025 presentations highlighted 50.4-month median PFS data and first-in-human results from novel CAR-T platform
Open the full interactive Legend Biotech report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.